BristolBridge Seminar - Development of novel anti-infectives targeting bacterial metallo-enzymes
Dr Martin Everett, Chief Scientific Officer, ANTABIO
Biomedical Sciences, C44
BristolBridge Seminar - Dr Martin Everett, ANTABIO
Development of novel anti-infectives targeting bacterial metallo-enzymes
ANTABIO (http://www.antabio.com/) is a private biopharmaceutical company developing the next generation of antibiotic resistance breakers in areas of highest unmet medical needs.
Dr Martin Everett has over 25 years’ experience in academia, pharmaceutical R&D (GSK) and biotechnology (MerLion, ANTABIO) as a drug discovery scientist with a particular interest in antibiotic resistance/persistence mechanisms. At ANTABIO, Martin leads the internal discovery group, and has responsibility for external research collaborations. He is Principal Investigator for ANTABIO’s Pseudomonas biofilms inhibitors programme, supported by a Wellcome Trust Seeding Drug Discovery Award. Antabio have just been awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in cystic fibrosis patients.
Recently, the spotlight has been thrown on AMR (Antimicrobial Resistance) as a major public health threat. Current antibacterial drugs are increasingly ineffective due to the evolution and spread of resistant strains. Too few new drugs are in development and new incentives are being proposed to stimulate the pharmaceutical industry and academia to respond before it is too late. ANTABIO are responding to this challenge with a focus on developing novel compounds which target bacterial metallo-enzymes that can be given alongside current treatments to improve or restore their effectiveness.
For further information or enquiries, please contact the BristolBridge Manager firstname.lastname@example.org